Stock Watch: Poxel Passes Go…But To Where?
Japanese Approval Is No Guarantee Of Commercial Success
Poxel’s shift to new therapeutic areas may be necessary despite Japan’s approval for its diabetes drug. Twymeeg looks set to be hamstrung by placebo-controlled studies without outcomes data.
